hotspot -WSS

hotspot

author：fashion 2025-09-28 21:57:12 - browse：96

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Startup Neumora takes a novel depression drug to Phase 3

explore

Wikipedia

WSS

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

AdventHealth escalates lawsuit against insurance vendor Multiplan

Feng Zhang, Grail founder join forces on new gene editing startup

U.K. sequencing study surfaces new findings about tumor DNA

Videos point to link between seizures and unexplained toddler deaths

A public scorecard can help hold safety

leisure time

hotspot

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Chronically ill young patients struggle to find fertility info

BioMarin wins approval for gene therapy to treat hemophilia A

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

How one medical school became remarkably diverse

In early work, researchers turn to CRISPR to treat Alzheimer's

Medical leaders decry Supreme Court decision on affirmative action

AI can’t replace a physician’s gut feeling

What does generative AI mean for health care? We asked experts

In early work, researchers turn to CRISPR to treat Alzheimer's

explore

New weight loss drugs work. But how can they best be used?

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

As digital health tech proliferates, a new institute aims to cut through hype

Medicare to cover more brain scans for Alzheimer’s patients

In early work, researchers turn to CRISPR to treat Alzheimer's

A single drug, study failures leave Anavex with nothing but cash

explore

Wikipedia

Wikipedia

entertainment